CXCL9 and EASIX for Prediction of Acute Graft Versus Host Disease
ConditionGVHD,Acute
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorHenry Ford Health System
About this trial
The prediction of severe acute GVHD before it occurs is of high importance for ensuing clinical decisions and overall success of allogeneic SCT. The key immunologic signatures associated with clinical outcomes after different graft versus host disease prophylaxis methods or peripheral blood stem cell transplant are largely unknown.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients >18 year old admitted for allo SCT PB for malignant disease.
Disqualifiers
None
Trial population
Patients \>18 year old admitted for allo SCT PB for malignant disease
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
blood sample
Diagnostic testblood sample to check CXCL9 and EASIX at day 28 post stem cell transplant
Treatment groups
No treatment groups listed
Trial outcomes
Primary outcomes
1
predictors of acute GVHD
CXCL9 combined with EASIX can be used as predictors of acute GVHD
Time frame
CXCL9 combined with EASIX calculated at day 28 +/- 2 post SCT can be used as predictors of acute GVHD by day 100.Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov